首页 | 本学科首页   官方微博 | 高级检索  
检索        

体外药敏试验ATP-TCA与流式细胞仪在肝癌化疗中的应用
引用本文:褚忠华,陈涛,区庆嘉,王捷,赵海燕,魏菁,刘建平.体外药敏试验ATP-TCA与流式细胞仪在肝癌化疗中的应用[J].中华肝胆外科杂志,2002,8(12):728-731.
作者姓名:褚忠华  陈涛  区庆嘉  王捷  赵海燕  魏菁  刘建平
作者单位:1. 510120,广州市,中山医科大学孙逸仙纪念医院普通外科
2. 510120,广州市,中山医科大学孙逸仙纪念医院医研中心
基金项目:广东省社会发展重大科技项目 (NO :2KM 0 45 0S)
摘    要:目的 探讨体外化疗药敏试验系统(ATP-TCA系统)联合流式细胞仪(FCM)在肝癌化疗中的应用及其结果之间的关系。方法 取24例肝癌切除,活检或穿刺组织行体外药敏试验和流式细胞仪P170检测,并分析二者间的关系。结果 ATP-TCA的可评估率为91.67%;10种化疗药物的敏感率分别为:氟尿嘧啶5.00%,诺消灵5.00%,顺铂14.26%,足叶乙甙19.05%,草酸铂19.05%,丝裂霉素23.81%,表阿霉素28.57%,开普拓45.46%,健择47.62%,泰素63.64%;P170检测阳性率为57.14%;丝裂霉素,表阿霉素的敏感率在P170阴性表达时高,开普拓健择,泰素的敏感率高且在P170阳性表达和阴性表达时无显著差异。结论 ATP-TCA法联合FCM可较好用于肝癌化疗药物的筛选;丝裂霉素,表阿霉素可用于P170阴性表达的病人,开普拓,健择,泰素可用于P170阳性表达的病人。

关 键 词:体外药敏试验  ATP-TCA  流式细胞仪  肝癌  化疗  多耐药基因
修稿时间:2001年11月2日

Application of in vitro ATP-TCA and FCM in chemotherapy of primary liver cancer
CHU Zhonghua,CHEN Tao,OU Qingjia,et al..Application of in vitro ATP-TCA and FCM in chemotherapy of primary liver cancer[J].Chinese Journal of Hepatobiliary Surgery,2002,8(12):728-731.
Authors:CHU Zhonghua  CHEN Tao  OU Qingjia  
Institution:CHU Zhonghua,CHEN Tao,OU Qingjia,et al. Department of General Surgery,Sun Yet-Sen Memorial Hospital,Sun Yet-Sen University of Medical Sciences,Guangzhou 510120,P. R. China
Abstract:Objective To study the application of in vitro ATP tumor chemosensitivity assay (ATP-TCA) and flow cytometry (FCM) in chemotherapy of primary liver cancer. Methods The specimens of primary liver cancer from 24 patients were tested by ATP-TCA and FCM. Results Evaluable test results were achieved in 22 of the 24 patients and the evaluability was 91.6%. The sensitive rates of 5-Fluoruracil (5-Fu), mitoxantron (MIT), cisplatin (CDDP), etoposid (Vp-16), oxaliplatin (OXA), mitomycin C (MMC), epirubicin (EPI), irinotecan (CPT), gemcitabine (GEM) and paclitaxl (TAX) were 5.00%, 5.00%, 14.29%, 19.05%, 19.05%, 23.81%, 28.57%, 45.46%, 47.62% and 63.60%, respectively. The positive rate of P 170 was 57.14%. The sensitive rates of MMC and EPI were higher in P 170 negative patients than in P 170 positive ones. The sensitive rates of CPT, GEM and TAX were high and there was no difference in sensitivity between different P 170 expression patterns. Conclusions ATP-CTA and FCM can be applied in screening of chemotherapeutic agents for primary liver cancer. MMC and EPI can be used in patients with negative P 170 expression and CPT, GEM and TAX in those with positive P 170 expression.
Keywords:Carcinoma  hepatocellular  In vitro chemosensitivity assay  Flow cytometry  Primary liver cancer  Multidrug resistance  P    170
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号